HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Greenwich LifeSciences and raised the price target from $36 to $38.
August 23, 2024 | 11:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Greenwich LifeSciences and increased the price target from $36 to $38, indicating positive sentiment and potential upside.
The Buy rating and increased price target suggest that the analyst expects the stock to perform well, which could lead to positive investor sentiment and a potential increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100